No Photo Available

Last Update

2016-12-07T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Lloyd Tillman?

Dr. Lloyd G. Tillman

Executive Director Pharm Development

Isis Pharmaceuticals , Inc.

Direct Phone: (760) ***-****       

Email: l***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Isis Pharmaceuticals , Inc.

2855 Gazelle Court

Carlsbad, California 92010

United States

Company Description

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiov ... more

Find other employees at this company (396)

Background Information

Employment History

Executive Director Pharm Development

IONIS Education Group

Associate Director, Division Prod Qual Rsch, CDER

Food and Drug Administration

Group Leader, Pharm. Development

Burroughs Wellcome Fund

Education

Ph.D.

Web References (21 Total References)


Isis: Investors and Media: Press Release

ir.isispharm.com [cached]

Lloyd G. Tillman , Ph.D., Executive Director of Pharmaceutical Development of Isis has been awarded the American Pharmacists Association's (APhA) 2009 Ebert Prize. Dr. Tillman received the award at the APhA Annual Meeting and Exposition, April 3-6, 2009

...
Lloyd Tillman
...
"We are pleased that Dr. Tillman was recognized by the APhA to receive this award on our seminal work in advancing the oral delivery of antisense drugs.
...
Lloyd Tillman


CARLSBAD, Calif., April 6 ...

phx.corporate-ir.net [cached]

CARLSBAD, Calif., April 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Lloyd G. Tillman, Ph.D., Executive Director of Pharmaceutical Development of Isis has been awarded the American Pharmacists Association's (APhA) 2009 Ebert Prize. Dr. Tillman received the award at the APhA Annual Meeting and Exposition, April 3-6, 2009, in San Antonio, TX, for work published in the Journal of Pharmaceutical Sciences entitled "Oral Delivery of Antisense Ol...


CARLSBAD, Calif., April 6 ...

phx.corporate-ir.net [cached]

CARLSBAD, Calif., April 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Lloyd G. Tillman, Ph.D., Executive Director of Pharmaceutical Development of Isis has been awarded the American Pharmacists Association's (APhA) 2009 Ebert Prize. Dr. Tillman received the award at the APhA Annual Meeting and Exposition, April 3-6, 2009, in San Antonio, TX, for work published in the Journal of Pharmaceutical Sciences entitled "Oral Delivery of Antisense Ol...


CARLSBAD, Calif., April 6 ...

phx.corporate-ir.net [cached]

CARLSBAD, Calif., April 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Lloyd G. Tillman, Ph.D., Executive Director of Pharmaceutical Development of Isis has been awarded the American Pharmacists Association's (APhA) 2009 Ebert Prize. Dr. Tillman received the award at the APhA Annual Meeting and Exposition, April 3-6, 2009, in San Antonio, TX, for work published in the Journal of Pharmaceutical Sciences entitled "Oral Delivery of Antisense Ol...


Isis Pharmaceuticals, Inc. - Isis Scientist Awarded 2009 Ebert Prize

ir.isispharm.com [cached]

CARLSBAD, Calif., April 6, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Lloyd G. Tillman, Ph.D., Executive Director of Pharmaceutical Development of Isis has been awarded the American Pharmacists Association's (APhA) 2009 Ebert Prize. Dr. Tillman received the award at the APhA Annual Meeting and Exposition, April 3-6, 2009, in San Antonio, TX, for work published in the Journal of Pharmaceutical Sciences entitled "Oral Delivery of Antisense Oligonucleotides in Man." His co-authors are Richard S. Geary, Ph.D. and Gregory E. Hardee, Ph.D. (1)

...
I would like to recognize my co-authors, whose advice and hard work contributed significantly to this publication," said Lloyd Tillman. "Our work demonstrated, for the first time, that antisense drugs could be administered orally. The feasibility of oral administration has dramatically broadened the therapeutic and commercial potential of antisense drugs."
The research, which was published in January 2008, provided proof-of-concept for the oral administration of antisense drugs in a single-dose study in man. Scientists at Isis continue to research advances to enhance the pharmaceutical properties of antisense drugs, including oral bioavailability.
"We are pleased that Dr. Tillman was recognized by the APhA to receive this award on our seminal work in advancing the oral delivery of antisense drugs.
...
(1) Lloyd Tillman, Richard S. Geary, Gregory E. Hardee.

Similar Profiles

Other People with this Name

Other people with the name Tillman

Alphonso Tillman
Professional 50 States Protection LLC

Darryl Tillman
Rollins , Inc.

Sandra Tillman
MD Anderson Cancer Center

Scott Tillman
Lipscomb University

Jocelyn Tillman
Riverside Health of Maryland Inc

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory